PLK1 and breast carcinoma: In line with our findings, several other studies reported that the combination of Plk1 inhibition with radiotherapy leads to synergistic cell killing in vitro in multiple cancer types such as breast cancer, NSCLC, cervical epithelial adenocarcinoma, medulloblastoma, osteocarcinoma, glioblastoma, Merkel cell carcinoma, colorectal cancer, bladder carcinoma, oral cancer, and esophageal squamous cell carcinoma [8,28,29,30,31,32,33,34,35,36,37,38,39,40].